Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance

Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q2 EPS of $0.43, $0.28 better than the analyst estimate of $0.15. Revenue for the quarter came in at $37.6 million versus the consensus estimate of $26.88 million.

GUIDANCE:

Eton Pharmaceuticals Inc. sees FY2026 revenue of $145 million, versus the consensus of $121 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c